Researchers with the International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI) have built tiny particles that resemble HIV on their outside and used them to provoke an immune response in animals. Their work, which was published today in the journal Cell Reports, could advance the design of an effective AIDS vaccine.
23 May 2016 | IAVI
The US National Institute of Allergy and Infectious Diseases (NIAID) and its partners have decided to advance an experimental HIV vaccine regimen into a large clinical trial, the first for seven years. This new study, called HVTN 702, is designed to determine whether the vaccine is safe, tolerable and effective at preventing HIV infection among South African adults. The trial will begin in November 2016, pending regulatory approval. It will recruit 5400 HIV-uninfected men and women aged 18 to 35 years who are at risk for HIV infection.
18 May 2016 | National Institute of Allergy and Infectious Diseases
he new target is part of the HIV envelope called the 'fusion peptide', and its structure is simpler than the sites that past HIV vaccine attempts have focussed on. This offers hope that, this time, we might have more luck getting the body to recognise and shut down the virus before it's too late.
16 May 2016 | ScienceAlert
The research showed that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens (molecules capable of inducing an immune response).
13 April 2016 | EASL press release
Monkeys in the study did not show signs of persistent infection until they were exposed to nearly 70,000 times the average amount of virus an infected man passes to a partner during intercourse.
12 April 2016 | UPI.com
UNITAID has published a report that asks how best to separate the costs of research and development for vaccines, medicines and diagnostics from their prices – a concept known as “delinkage”.
02 March 2016 | UNITAID
Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.
21 February 2016 | Boston Globe
Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.
03 February 2016 | EATG
It isn’t too out of the ordinary for Gates Foundation grant awards to soar into the eight- and even nine-figure range. So, its $20 million grant to Moderna Therapeutics to support its continuing development of a novel but promising HIV prevention therapy isn’t particularly extraordinary. But what is unusual...is that the total potential commitment from the foundation could reach upwards of $100 million—around 70 percent of the Gates Foundation’s HIV/AIDS grants for all of last year.
27 January 2016 | Inside Philanthropy
The European Commission has granted over 22 million Euros to the European HIV Vaccine Alliance (EHVA) to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. The grant is supplemented with additional 6 million Euros from the Swiss government for the Swiss project partners.
27 January 2016 | Eurekalert Inf Dis